JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Visualized chemiluminescence immunoassay for simultaneous detection of multiple lung cancer markers based on spatially resolved microfluidic paper chip device

  • 0School of Pharmacy, Anhui Medical University, Hefei, 230032, PR China.
Talanta +

|

May 23, 2025

|

May 23, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

A novel chemiluminescent hydrogel integrated with a 3D microfluidic paper-based analytical device (3D μPAD) enables visual detection of lung cancer markers. This portable biosensor offers rapid, sensitive, and simultaneous identification of NSE and CEA in real samples.

Area Of Science

  • Biomedical Engineering
  • Analytical Chemistry
  • Materials Science

Background

  • Lung cancer is the leading cause of cancer-related mortality worldwide.
  • Early detection of lung cancer is crucial for improving patient survival rates.
  • Tumor markers play a vital role in assessing cancer risk and aiding diagnosis.

Purpose Of The Study

  • To develop a visual biosensor for the simultaneous detection of multiple lung cancer markers.
  • To synthesize a glow-type chemiluminescent hydrogel (SCG-Co<sup>2+</sup>-luminol) for enhanced signal generation.
  • To integrate the hydrogel with a 3D microfluidic paper-based analytical device (3D μPAD) for a portable detection platform.

Main Methods

  • Synthesis of SCG-Co<sup>2+</sup>-luminol hydrogel with a porous structure for prolonged chemiluminescence (CL).
  • Fabrication of a 3D μPAD with six detection areas for spatial resolution-based multiplexed detection.
  • Development of a visual CL immunoassay for simultaneous quantification of NSE and CEA using smartphone imaging and Image J analysis.

Main Results

  • The SCG-Co<sup>2+</sup>-luminol hydrogel exhibited strong CL signal lasting over 60 minutes upon reaction with H<sub>2</sub>O<sub>2</sub>.
  • The 3D μPAD-based biosensor demonstrated a linear relationship between CL intensity and concentrations of NSE and CEA.
  • Achieved a wide linear range (0.1-10000 pg/mL) with low detection limits (0.032 pg/mL for NSE, 0.036 pg/mL for CEA).

Conclusions

  • The developed visualized CL immunoassay is highly sensitive, rapid, and portable.
  • The method was successfully validated for detecting NSE and CEA in real patient samples.
  • This innovative biosensor shows significant promise for multi-component lung cancer marker analysis and early diagnosis.

Keywords: